Drug Discovery
Drug Discovery
Drug Discovery

Platform

Drug Discovery /
Functional Genomics

Pooled high content phenotypic screens of genes and drugs. Compatible with multiple libraries including CRISPR gRNAs, shRNAs, antibodies, and even small molecule compounds.

Pooled High-Content Screening of Genes and Drugs

Our Solution for Drug Discovery

Image-based high-content screening (HCS) is a powerful method for identifying genes and compounds that induce physiologically relevant disease-linked cellular phenotypes. However, it is time-consuming and expensive due to its reliance on well-to-well imaging of microplates.
Using ThinkCyte’s proprietary machine Vision-based Cell Sorting technology, we have developed a new method that enables high-throughput image-based HCS in a pooled format. This novel method is compatible with various types of libraries, including CRISPR gRNAs, shRNAs, antibodies, peptides, and small molecule compounds.

From array to pool

From array to pool

Key Advantages of Our
Technology

Compatible with a wide range of libraries

Compatible with
a wide range of libraries

Small molecule libraries, CRISPR, shRNA, peptide, phage libraries, etc.

High speed sorting

High speed sorting

・Pathway-specific libraries: 1–3 h
・Whole-genome libraries: 8–12 h
・Compound libraries (~100,000 compounds): 1–3 d

For precious cells

For precious cells

Only a few hundred cells per gene/compound are required for screening

Link genotypes to phenotypes

Link genotypes to phenotypes

Image data is linked to the NGS data

Phenotype-driven Target Validation in Drug Discovery

In the phenotypic screening process, identification of disease relevant phenotypes is crucial. Our screening platform is able to detect various types of phenotypes, such as changes in protein localization, aggregation, and cell and organelle morphology, using fluorescence reporters. Furthermore, our proprietary machine vision-based classification technique can discriminate morphological differences of cells including live and apoptotic cells, differentiated and undifferentiated cells, and healthy and disease relevant cells, without the use of molecular labels. These label-free phenotypes can be also used in our screening system.

Phenotype-driven

Disease-relevant phenotypes of cells

Fluorescence

Phenotype
of Interest

Nuclear
Translocation

Nuclear Translocation

PPI,
Aggregation

PPI, Aggregation

Organelle
Morphology

Organelle Morphology
Imaging
Flow
Cytometer
(Amnis)
  • LPS(+)

    LPS(+)
  • LPS(-)

    LPS(-)
  • Untreated

    Untreated
  • Nutlin-3

    Nutlin-3
  • Mitochondria

    Mitochondria
  • Lysosome

    Lysosome

Label-free

Apoptotic Status

Differentiation

Disease vs Healthy

Imaging
Flow
Cytometer
(Amnis)
  • Live

    Live

  • Apoptotic

    Apoptotic

  • Differentiated

    Differentiated

  • Undifferentiated

    Undifferentiated

  • Cancerous

    Cancerous

  • Healthy

    Healthy

Screening Workflows

Our screening platform enables image-based high-content screens in a pooled format and can dramatically accelerate the screening process while reducing costs. It is compatible with a wide range of libraries, including CRISPR gRNAs, shRNAs, antibodies, peptides, and small molecule compounds.

Pooled screening of genes

Our technology is applicable for genetic screens using lentivirus libraries, including CRISPR libraries.

Pooled screening of genes

Pooled screening of drugs

Combining our proprietary VisionSort technology with DNA barcoding and droplet techniques, image-based high-content screens can be performed for small molecule libraries in a pooled format as well.

Pooled screening of drugs